Overview

Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Sevelamer